Evidence map›Paper›PMID 33939102›Full record

ArticleTranslational stroke research2021

Electrophilic and Drug-Induced Stimulation of NOTCH3 N-terminal Fragment Oligomerization in Cerebrovascular Pathology.

K Z Young, N M P Cartee, S J Lee, S G Keep, M I Ivanova, Michael M Wang

Open access · greenAbstract read
In one paragraph

Article in Translational stroke research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

K Z Young *Department of Neurology, University of Michigan, 7725 Medical Science Building II Box 5622, 1137 Catherine St., Ann Arbor, MI, 48109-5622, USA.
N M P Cartee *Department of Neurology, University of Michigan, 7725 Medical Science Building II Box 5622, 1137 Catherine St., Ann Arbor, MI, 48109-5622, USA.
S J LeeDepartment of Neurology, University of Michigan, 7725 Medical Science Building II Box 5622, 1137 Catherine St., Ann Arbor, MI, 48109-5622, USA.
S G KeepDepartment of Neurology, University of Michigan, 7725 Medical Science Building II Box 5622, 1137 Catherine St., Ann Arbor, MI, 48109-5622, USA.
M I IvanovaDepartment of Neurology, University of Michigan, 7725 Medical Science Building II Box 5622, 1137 Catherine St., Ann Arbor, MI, 48109-5622, USA.
Michael M WangDepartment of Neurology, University of Michigan, 7725 Medical Science Building II Box 5622, 1137 Catherine St., Ann Arbor, MI, 48109-5622, USA. micwang@umich.edu.
University of Michigan–Ann Arbor · US

Funding

MICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3M
Integrating Quality Control: Studies of UBQLN2 in Age-Related NeurodegenerationR01NS096785 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI IVANOVA, MAGDALENA I, PAULSON, HENRY L · 2016 to 2020
$3.4M
Training Program in Translational Cardiovascular Research and EntrepreneurshipT32HL125242 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MICHELE, DANIEL E · 2015 to 2024
$1.9M
NOTCH3 N-terminal fragmentation in cerebral small vessel diseaseR01NS099160 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WANG, MICHAEL M · 2018 to 2022
$1.6M
Promoting Diversity of Future ScientistsR25HL108842 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Susan V Brooks · 2011 to 2026
$1.3M
Identification and functional analysis of novel human-specific small vessel disease proteinsR21NS099783 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WANG, MICHAEL M · 2016 to 2017
$347k
Pathological protein generation in cerebral small vessel diseaseI01BX003824 · VA · VETERANS HEALTH ADMINISTRATION · PI Michael M Wang · 2017 to 2026
–
Transformation of NOTCH3 protein in cerebral small vessel diseaseI01BX003855 · VA · VETERANS HEALTH ADMINISTRATION · PI WANG, MICHAEL M · 2018 to 2021
–
BLRD VA I01 BX003824BLRD VA I01 BX003855NHLBI NIH HHS R25 HL108842NHLBI NIH HHS T32 HL125242NIGMS NIH HHS T32 GM007863NINDS NIH HHS R01 NS096785NINDS NIH HHS R01 NS099160NINDS NIH HHS R21 NS099783
6 · The paper itself

Abstract

Small vessel disease is a prevalent age-related condition linked to increased risk of dementia and stroke. We investigate the most commonly inherited form, CADASIL, caused by cysteine-involving mutations in NOTCH3. Recent studies highlight accumulation of NOTCH3 N-terminal fragmentation product (NTF) in disease. In vitro, NTF is capable of both spontaneous and catecholamine-enhanced cysteine-mediated oligomerization. Despite well-characterized genetic influence on CADASIL, environmental effects, including medication usage, on disease remain unclear. We studied effects of assorted electrophilic compounds and drugs on NTF oligomerization by SDS-PAGE and dynamic light scattering. We then examined direct proton pump inhibitor-NTF binding with antibodies designed against proton pump inhibitor-labeled proteins and mass spectrometry. Finally, we used monoclonal NTF antibodies with Proximity Ligation Assay to identify NTF oligomers in 3 CADASIL and 2 age-matched control brains. We identified enhancement of NTF oligomerization by two electrophilic cysteine-modifying compounds, N-ethylmaleimide and iodoacetamide, and an electrophilic compound capable of oxidizing cysteines, ferric chloride. Electrophilic clinical drugs (fenoldopam, omeprazole, tenatoprazole, lansoprazole, and rabeprazole) also promoted oligomerization, and we identified direct omeprazole-NTF and tenatoprazole-NTF complexes. Additionally, we provide novel evidence of NTF multimers in human CADASIL brains. A broad array of electrophilic chemicals, including clinically relevant drugs, influences oligomerization of a pathological CADASIL protein, providing mechanistic insight into disease protein oligomerization. We posit that environmental influences, which may include usage of electrophilic drugs, may affect CADASIL presentations.

Indexed as

CADASILPharmaceutical PreparationsBrainCysteineHumansMutationReceptor, Notch3Receptors, NotchCysteineNOTCH3 protein, humanPharmaceutical PreparationsReceptor, Notch3Receptors, NotchCysteineNOTCH3OligomerizationProton pump inhibitors

Identifiers

PMID33939102
PMCPMC8557116
OpenAlexW3157532991

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.